Davita Inc vs SiTime Corporation — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while SiTime Corporation trades at $615 (market cap $19.42B). The key difference: SiTime Corporation is the larger of the two by market cap, and Davita Inc is more actively traded (582,204 versus 360,307). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and SiTime Corporation for 18 Days on average.
| DVA | SITM | |
|---|---|---|
Market Cap | $11.29B | $19.42B |
Volume | 582,204 | 360,307 |
Sector | Health | Technology |
52-Week High | $240.96 | $901.60 |
52-Week Low | $103.87 | $252.76 |
Typical Hold Time | 114 Days | 18 Days |
Enterprise Value | $24.01B | $18.82B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
SITM trades at $612.37, down 7.94% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with a 126.5% revenue surge to $157.43M and achieving its first GAAP profit. Analyst consensus is unanimously bullish with a $751.43 price target, citing AI-driven growth and market leadership in MEMS timing solutions.
The outlook is positive, driven by AI infrastructure demand and operational leverage, but risks include high valuation multiples, negative 2025 net income, and insider selling. The stock offers significant upside potential if growth continues, though execution and market volatility pose challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →